openPR Logo
Press release

Opioid Induced Constipation Treatment Market to Record an Exponential CAGR by 2023

07-19-2018 09:29 PM CET | Health & Medicine

Press release from: Transparency Market Research

Opioid Induced Constipation Treatment Market to Record

In a highly consolidated Opioid Induced Constipation Treatment Market, the top three companies, namely Takeda, Boehringer Ingelheim, and Valeant Pharmaceuticals International Ltd collectively held 91.8% in the overall market in 2014. However, Takeda Pharmaceuticals Company Ltd enjoys clear dominance because of popularity of its approved drug Amitiza.

Innovation of novel drugs is the key growth strategy players in the opioid induced constipation treatment market have resorted to. This is to serve the demand for new drugs that are less likely to face competition in this largely untapped market. Savvy players are vying to tap into the opportunities that are brimming in this market.

According to a report by Transparency Market Research (TMR), the global opioid induced constipation treatment market is likely to rise at a whopping 31.2% CAGR vis-à-vis revenue for the forecast period between 2015 and 2023. This will translate the demand in the market into a revenue of US$4.81 bn by 2023-end considerably up from US$731.2 mn in 2016. While chloride channel activators stood as the leading drug class in the opioid induced constipation treatment in 2016, mu-opioid receptor antagonists are likely to overtake over the report’s forecast period. This is mainly because of approvals received by an increasing number of mu-opioid receptor antagonists and their higher efficacy over other drugs. Region-wise, North America is likely to continue to lead in the opioid induced constipation treatment market until 2023.

Request to View Sample of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6862

Across the world, the number of individuals suffering from opioid induced constipation is on the rise. As per statistics of the American Academy of Pain Medicine, in 2013, almost 100 million patients in the U.S. were suffering from opioid induced constipation. The number is predicted to rise as the number of individuals consuming opioid drugs increases. In addition, rising awareness about the commercial availability of host of opioid drugs is also leading to their adoption for chronic pains.

Presently, there are several pipeline drugs for the treatment of opioid induced constipation. The approval of these drugs will foster the growth of this market which currently remains largely untapped. The choice of drugs for the treatment of opioid induced constipation has been shaky, but approval of highly targeted drugs is likely to provide impetus to this market’s growth. PAMORA class of drugs are in the pipeline to treat opioid induced constipation without interfering opioid’s action on the patient.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6862

Developed regions, such as North America, that are early adopters of modern medicine account for sizeable contribution to the opioid induced constipation treatment market. This, along with a large percentage of population suffering from chronic diseases, resort to opioids for the primary condition This in turn will fuel the demand for such drugs to help people with opioid induced constipation, a secondary condition. As per the American Society of Interventional Pain Physicians, in 2013, the U.S. alone accounted for almost 80% of global consumption of opioids. This is mainly because of legal approval of opioids for pain treatment by the U.S. FDA and substantially high consumption of opioids for long term treatment of chronic pain.

On the flip side, drugs for opioid induced constipation face competition from standard laxatives that are considered as the first line of treatment. In addition, the long term negative effects of opioid induced constipation drugs have so far not been fully documented, challenging the opioid induced constipation treatment market.

View Report -

https://www.transparencymarketresearch.com/opioidinduced-constipation-treatment-market.html

About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Opioid Induced Constipation Treatment Market to Record an Exponential CAGR by 2023 here

News-ID: 1136436 • Views:

More Releases from Transparency Market Research

Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights for the USD 15.9 Bn Market 2022-2031
Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights f …
The global handheld marijuana vaporizer market has witnessed remarkable growth in recent years, attributed to the increasing acceptance of medicinal marijuana and the demand for convenient and discreet consumption methods. Valued at US$ 5 billion in 2021, the market is projected to surge at a CAGR of 13.4% to reach US$ 15.9 billion by 2031. This article delves into the factors driving this growth, the evolving market landscape, and the
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And Competitors
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And …
The COVID-19 pandemic has precipitated a remarkable surge in the demand for disinfectant products, with a notable emphasis on disinfectant wipes as an essential tool in maintaining hygiene and preventing the spread of pathogens. This research report delves into the multifaceted landscape of the disinfectant wipes market, elucidating key trends, drivers, and innovations shaping the industry. 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=70359 Key Players and Market Developments Key players
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Study
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Stud …
The global 𝐭𝐢𝐬𝐬𝐮𝐞 𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 reached a value of US$ 1,056.4 million in 2017 and is projected to nearly triple to US$ 2,903.3 million by 2026, with a robust Compound Annual Growth Rate (CAGR) of approximately 12.0% from 2018 to 2026. Factors such as increasing awareness about tissue donation, technological advancements, and a growing target patient population are anticipated to propel market growth during this period. Moreover, the market is expected
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
This report by Transparency Market Research, Inc. assesses the present state and future growth potential of the global 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐜𝐥𝐨𝐬𝐮𝐫𝐞 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭. It features a comprehensive executive summary, offering insights into various segments of the market. Additionally, the report provides detailed analysis and data on product, access type, application, end user, and regional segments within the global market. Vascular closure devices is estimated to reach a value of ~US$ 1 Bn

All 5 Releases


More Releases for Opioid

MEDICAL MARIJUANA AND THE OPIOID CRISIS
Marijuana from the Cannabis plant is classified as a psychoactive drug used for medical or recreational purposes. Although it has been used for decades, in the U.S., it is still illegal under federal law to use and possess marijuana. Get PDF Sample Brochure of this report at: https://decisionmarketreports.com/request-sample/1247622 Nevertheless, at the state level, policies regarding the medical and recreational use of Cannabis vary greatly, and in many states conflict significantly with federal
Analgesics Market Driven by Growing Opioid and Non-Opioid Medicine Sales
The application of opioids for the treatment of pain due to cancer, surgery, injury and trauma makes it a bright prospect in the augmentation of analgesics market. Along with opioid drugs, non-opioid is expected to underpin the analgesics market. Prominent companies are grappling to invest in research and development to augment non-opioid drugs through the application of innovative drug delivery approaches which will help in alleviating pain for considerably longer
Opioid Induced Constipation Treatment Market: Mu-opioid Receptor Antagonists to …
Takeda Pharmaceuticals Company, Ltd., with its approved drug Amitiza, holds a majority share in the global market for opioid induced constipation treatment. In 2014 the top three players - Takeda, Valeant Pharmaceuticals International, Ltd., and Boehringer Ingelheim – operated on a collective share of 91.8% of the global market. This is a highly consolidated market but with a large scope for the prominent players to penetrate regions other than North
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Opioid Induced Side Effects Treatment Market
Opioids are the class of drug that include strong pain relievers and illegal drugs such as heroin and illicit pain relievers for example hydrocodone, oxycodone, morphine and fentanyl. Also they are available legally on prescription. These drugs interact with opioid receptors on nerve cells in body and are well known for the management of acute pain and cancer related pain among patients of all age group. However, opioid drugs use in
Opioid Induced Side Effects Treatment Market
Opioids are the class of drug that include strong pain relievers and illegal drugs such as heroin and illicit pain relievers for example hydrocodone, oxycodone, morphine and fentanyl. Also they are available legally on prescription. These drugs interact with opioid receptors on nerve cells in body and are well known for the management of acute pain and cancer related pain among patients of all age group. However, opioid drugs use in